Following FDA approval of lifileucel for advanced melanoma in early 2024, U.S. centers have been learning how to best deliver this novel “living” drug. For #ASCODailyNews, @maxjulve.bsky.social & @drbetofmdphd.bsky.social discuss the real-world challenges facing clinicians: https://bit.ly/48nBPor
Dr. Monty Pal of @cityofhope.bsky.social & @drbonillaonc.bsky.social of St. Luke's University Health Network discuss the risks of implementing #AI in clinical practice & approaches to help oncologists maintain their decision-making agility on the latest #ASCODailyNews Podcast: https://bit.ly/4dQrp43
Dr. Sumanta Pal of @cityofhope.bsky.social discusses the impact of the groundbreaking AQUILA trial in high-risk smoldering multiple myeloma with @vincentrk.bsky.social of Mayo Clinic & @szusmani.bsky.social of @mskcancercenter.bsky.social on the latest #ASCODailyNews Podcast: https://bit.ly/41FCEVw
Based on recent study results, bevacizumab + erlotinib could represent a significant advance for some renal cell carcinoma subtypes. For #ASCODailyNews, Dr. Pavlos Msaouel of @mdanderson.bsky.social discusses tailoring therapy for these rare and aggressive diseases: https://bit.ly/40zFjQj
For some patients with extensive-stage small cell lung cancer who achieve prolonged disease control with immunotherapy, an indefinite ICI break may be appropriate. Kelsey Pan, MD, MPH
& @ramalingammd.bsky.social discuss in a new editorial for #ASCODailyNews: https://bit.ly/40E8IJ7
🎙Dr. Monty Pal of @cityofhope.bsky.social and Dr. Andrea Apolo discuss the highlights from #GU26, including key research in bladder, kidney, and prostate cancers, on the latest episode of the #ASCODailyNews Podcast: https://bit.ly/40K3DyK
More from #ASCODailyNews: Phase 3 LITESPARK-011 results support belzutifan + lenvatinib as alt to cabozantinib for pts with aRCC after disease progression on anti–PD-L1/anti–PD-1 therapy. Read the full #GU26 article: dailynews.ascopubs.org/do/phase-3-l...
#ASCODailyNews: According to phase 3 LITESPARK-022 results, adding belzutifan to pembrolizumab improves DFS in pts with high-risk ccRCC. Read the full #GU26 article: dailynews.ascopubs.org/do/litespark...
Just presented at #GU26: EV + pembro before and after radical cystectomy yields significantly improved survival outcomes over GemCis followed by cystectomy in patients with MIBC, according to KEYNOTE-B15 results. #ASCODailyNews has more: https://bit.ly/47c4UCl
Breaking news from #GU26: Adding radium-223 to enzalutamide significantly prolongs OS in bone-dominant mCRPC, according to final results from phase 3 EORTC-1333/PEACE-3 trial. #ASCODailyNews has more: https://bit.ly/46Wrq22
Prostate Cancer Working Group 4: What Does Its Work Mean for the Busy Clinician? #ASCODailyNews speaks with PCCTC investigators Drs Michael Morris and Andrew Armstrong: dailynews.ascopubs.org/do/prostate-...
Combining HIF-2α inhibitors with TKIs may be an effective strategy to further improve outcomes for patients with mccRCC. Find out more in a new #ASCODailyNews editorial by Dr. Charles Nguyen and Dr. Sumanta Pal ahead of this week's #GU26: https://bit.ly/4aD9EC0
Drs. Sumanta K. Pal of @cityofhope.bsky.social and Atul Batra discuss the promise of low-dose immunotherapy to expand global access to cancer care while also reducing costs/toxicity on the latest episode of the #ASCODailyNews Podcast: https://bit.ly/3LSAv4T
ICYMI at #GI26: 2 novel KRAS-targeted treatments demonstrated manageable safety profiles and promising efficacy in early-phase studies of patients w/ PDAC and KRAS G12D mutations.
#ASCODailyNews has more: brnw.ch/21wZ79x
Now that #GI26 is over, catch up on all the news from the meeting with #ASCODailyNews. All coverage of the Symposium's top research can be found here: brnw.ch/21wZ1z3
Dr. Sumanta Pal of @cityofhope.bsky.social & @lymphomadoc.bsky.social of @mdanderson.bsky.social discuss two of the major challenges facing oncologists in 2026 on the latest episode of the #ASCODailyNews Podcast: brnw.ch/21wY5Tt
The treatment landscape for advanced UC has changed considerably in recent years. For #ASCODailyNews, Dr. Tom Powles and Dr. Catherine Graham discuss EV + pembro's place as standard 1L therapy & the potential for disease progression on avelumab: brnw.ch/21wXMbz
Please have a look at our editorial published in #ASCODailyNews
@ascocancer.bsky.social @antoniodalessio.bsky.social @cirocelsa.bsky.social
From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma dailynews.ascopubs.org/do/sorafenib...
🎙 What a great conversation with Dr Monty Pal of @cityofhope.bsky.social discussing some of the key abstracts from last week's #ASCOQLTY25 meeting on the @ascocancer.bsky.social #ASCODailyNews Podcast ➡️➡️ brnw.ch/21wWGAB
🎙Dr. Monty Pal of @cityofhope.bsky.social and @fumikochino.bsky.social of @mdanderson.bsky.social recap key abstracts from the recent #ASCOQLTY25 meeting on the latest episode of the #ASCODailyNews Podcast: dailynews.ascopubs.org/do/podcast-k...
Thanks @ASCO #ASCODailyNews for sharing our work on “What Is the Role of Machine Learning in Oncology Today?” led by @UCSDCancer fellow @TaliAzen
dailynews.ascopubs.org/do/role-mach...
Pembrolizumab is integral to the treatment of both early-stage and metastatic triple-negative #breastcancer. For #ASCODailyNews, Dr. Rita Nanda & Dr. Sarah Poland explore rechallenging with pembro after immune-related adverse events: brnw.ch/21wWdON
In a new editorial for #ASCODailyNews, Drs. Jasmin Hundal & Neil Iyengar discuss the rise of obesity-related cancers in younger adults and the need to integrate metabolic interventions into cancer prevention and survivorship strategies: brnw.ch/21wW1m6
Earlier this week, ASCO, @astro-org.bsky.social & @socsurgonc.bsky.social released a guideline with new recommendations for postmastectomy RT for patients with #breastcancer. #ASCODailyNews has more, including interviews with members of the joint task force: brnw.ch/21wVTiX
🎙 New host Dr. Sumanta K. Pal of @cityofhope.bsky.social & Dr. Kimmie Ng of @danafarber.bsky.social’s Young-Onset Colorectal Cancer Center discuss the alarming rise of early-onset GI cancers on the latest episode of the #ASCODailyNews Podcast: brnw.ch/21wUJUM
🎙 @realbowtiedoc.bsky.social & @rsedhom.bsky.social of @pennmedicine.bsky.social discuss a new strategy called precision palliative care – getting the right support to the right patient at the right time – on the latest episode of the #ASCODailyNews Podcast: brnw.ch/21wUB0b
ICYMI: In the era of EV plus pembro, where does radical cystectomy fit into treatment plans for patients with urothelial carcinoma? Dr. Sia Daneshmand provides a detailed overview for #ASCODailyNews: brnw.ch/21wUqrz
🎙️ Dr. Diwakar Davar and Dr. Jason Luke highlight exciting advances in drug development and other new IO data from #ASCO25 on a new episode of the #ASCODailyNews Podcast: dailynews.ascopubs.org/do/podcast-i... @news.upmc.com
🎙Dr. Neeraj Agarwal of @huntsmancancer.bsky.social and Dr. Jeanny Aragon-Ching of @inovahealth.bsky.social Schar Cancer highlight key innovations in GU cancer research from #ASCO25 on the latest episode of the #ASCODailyNews Podcast: dailynews.ascopubs.org/do/podcast-i...
🎙️ @vamsivelcheti.bsky.social of @mayocliniccancer.bsky.social and Dr. Nate Pennell of @clevelandclinic.bsky.social highlight key abstracts in #SCLC and #NSCLC that stood out at #ASCO25 on the latest episode of the #ASCODailyNews Podcast: dailynews.ascopubs.org/do/podcast-l...
